Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells

Nutrition and Cancer

Volumn 61, Issue 3, 2009, Pages 322-331

  Berggren, Margareta ^a,b   Sittadjody, Sivanandane ^a   Song, Zuohe ^a,b   Samira, Jean Louis ^a,b   Burd, Randy ^a   Meuillet, Emmanuelle J ^a,b  

^a Environmental Research Laboratory   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CASEIN KINASE II; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SODIUM SELENITE; THIOREDOXIN; TUMOR SUPPRESSOR PROTEIN; GLUTATHIONE; PTEN PROTEIN, HUMAN; THIOREDOXIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; ENZYMOLOGY; HUMAN; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CASEIN KINASE II; CELL LINE, TUMOR; GLUTATHIONE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SODIUM SELENITE; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS; TUMOR SUPPRESSOR PROTEINS;

EID: 67649396127     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802521338     Document Type: Article

References (43)

1. Linder MC: Nutrition and metabolism trace elements. In: Nutritional biochemistry and metabolism with clinical applications, LinderMC (ed.). New York: Elsevier, 1985, 151-197.
2. Jiang C, Wang Z, Ganther H, and Lu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1, 1059-1066, 2002.
3. Wang Z, Jiang C, and Lu J: Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34, 113-1112, 2002.
4. WuY, Zu K,WarrenMA,Wallace PK, and Ip C:Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. MolCancer Ther 5, 246-252, 2006.
5. Lee YC, Tang YC, Chen YH, Wong CM, and Tsou AP: Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1. J Biol Chem 278, 39615-39624, 2003.
6. Freemerman AJ and Powis G: A RedOx-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells. Biochim Biophys Res Comm 274, 136-141, 2000.
7. Holmgren A: Thioredoxin and glutaredoxin systems. J Biol Chem 264, 13963-13966, 1989.
8. Gallegos A, Berggren M, Gasdaska JR, and Powis G: Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res 57, 4965-4970, 1997.
9. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, et al.: Distinct roles of thioredoxin in the cytoplasm and in the nucleus: a two-step mechanism of RedOx regulation of transcription factor NF-kappaB. J Biol Chem 274, 27891-27897, 1999.
10. Schenk H, Klein M, ErdbruggerW, DrogeW, and Schulze-Osthoff K: Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci USA 91, 1672-1676, 1994.
11. Abate C, Patel L, Rauscher FJ 3rd, and Curran T: RedOx regulation of fos and jun DNA binding activity in vitro. Science 249, 1157-1161, 1990.
12. Watson JA, Rumsby MG, and Wolowacz RG: Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem J 343, 301-305, 1999.
13. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, et al.: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17, 2596-2606, 1998.
14. Meuillet EJ, Mahadevan D, Berggren M, Coon A, and Powis G: Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429, 123-133, 2004.
15. Song Z, BrabantM, Saghafi N, Brabant M, andMeuillet EJ: The regulation of the tumor suppressor activity, PTEN by thioredoxin controls cell number and cell size. Exp Cell Res 313, 1161-1371, 2007.
16. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, et al.: Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276, 48627-48630, 2001.
17. Birle D, Bottini N, Williams S, Huynh H, deBelle I, et al.: Negative feedback regulation of the tumor suppressor PTENby phosphoinositide-induced serine phosphorylation. J Immunol 169, 286-291, 2002.
18. Maccario H, Perera NM, Davidson L, Downes P, and Leslie NR: PTEN is destabilized by phosphorylation on Thr366. Biochem J 405, 439-444, 2007.
19. Kirkpatrick DL, Watson S, Kunkel M, Fletcher S, Ulhaq S, et al.: Parallel syntheses of disulfide inhibitors of the thioredoxin RedOx system as potential antitumor agents. Anticancer Drug Des 14, 421-432, 1999.
20. Georgescu MM, Kirsch KH, Akagi T, Shishido T, and Hanafusa H: The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96, 10182-10187, 1999.
21. Oblong JE, Berggren M, and Powis G: Biochemical, structural and biological properties of human thioredoxin active site peptides. FEBS Lett 343, 81-84, 1993.
22. Biaglow JE, Donahue J, Tuttle S, Held K, Chrestensen C, et al.: A method for measuring disulfide reduction by cultured mammalian cells: relative contributions of glutathione-dependent and glutathione-independent mechanisms. Anal Biochem 281, 77-86, 2000.
23. Constantinescu A, Pick U, Handelman GJ, Haramaki N, Han D, et al.: Reduction and transport of lipoate by human erythrocytes. Biochem Pharmacol 50, 253-261, 1995.
24. Bustamante J, Lodge JKM, Marcoccl L, Tritschler HJ, Packer L, et al.: a-Lipoate in liver metabolism and disease. Free Radic Biol Med 24, 1023-1039, 1998.
25. Packer L, Roy S, and Sem CK: a-Lipoate: a metabolic antioxidant and potential RedOx modulator of transcription. Adv Pharmacol 38, 79-101, 1997.
26. Arner ESJ, Nordberg J, and Holmgren A: Effect of reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase, thioredoxin. Biochem Biophys Res Commun 225, 268-274, 1996.
27. Powell AA, LaRue JM, Batta AK, andMartinez JD: Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 356, 481-486, 2001.
28. Lim HW, Hong S, JinW, Lim S, Kim SJ, et al.: Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells. Exp Mol Med 37, 497-506, 2005.
29. Berggren M, Gallegos A, Gasdaska J, and Powis G: Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res 17, 3377-3380, 1997.
30. Nyman DW, Stratton SM, Kopplin MJ, Dalkin BL, Nagle RB, et al.: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev 28, 8-16, 2004.
31. Maehama T, Taylor GS, and Dixon JE: PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 70, 247-279, 2001.
32. Menter DG, Sabichi AL, and Lippman SM: Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9, 1171-1172, 2000.
33. Torres J and Pulido R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276, 993-998, 2001.
34. Kuo ML and Yang NC: Reversion of v-H-ras-transformed NIH3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem Biophys Res Commun 212, 767-775, 1995.
35. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, et al.: Decreased incidence of prostate cancer with selenium supplementation:results of a double-blind cancer prevention trial. Br J Urol 81, 730-734, 1998. (Pubitemid 28316638)
36. Vogt TM, Ziegler RG, Graubard BI, Swanson CA, Greenberg RS, et al.: Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103, 664-670, 2003.
37. Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr 128, 1845-1854, 1998.
38. Vliestra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, and Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58, 2720-2723, 1998.
39. Litchfield DW: Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369, 1-15, 2003.
40. Pinna LA: Protein kinase CK2: a challenge to canons. J Cell Sci 115, 3873-3878, 2002.
41. Al-Khouri AM, Ma Y, Togo SH, Williams S, and Mustelin T: Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3 beta. J Biol Chem 280, 35195-35202, 2005.
42. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, et al.: Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12, 668-677, 2005.
43. Ahmad KA, Wang G, and Ahmed K: Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of CK2 in prostate cancer cells. Mol Cancer Res 4, 331-338, 2006.